MedTrace Logo

Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen

NCT07137039 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-08-22

No results posted yet for this study

Summary

To evaluate the efficacy and safety of adebrelimab combined with TP chemotherapy regimen as neoadjuvant therapy for locally advanced hypopharyngeal cancer

Conditions

  • Locally Advanced Hypopharyngeal Cancer

Interventions

DRUG

Adebrelimab+Albumin paclitaxel +Cisplatin

1. Adebrelimab：1200mg, ivgtt, D1, Q3W; 2. Albumin paclitaxel :260mg/m2, ivgtt, D1, Q3W; 3. Cisplatin :60mg/m2, ivgtt, D1, Q3W.

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-20
Primary Completion
2027-08-20
Completion
2028-08-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07137039 on ClinicalTrials.gov